{"count": 5, "results": [{"_id": "35862706", "pmid": 35862706, "title": "Controlling Herpes Simplex Virus-Induced Immunoinflammatory Lesions Using Metabolic Therapy: a Comparison of 2-Deoxy-d-Glucose with Metformin.", "journal": "J Virol", "authors": ["Berber E", "Rouse BT"], "date": "2022-07-27T00:00:00Z", "doi": "10.1128/jvi.00688-22", "meta_date_publication": "2022 Jul 27", "meta_volume": "96", "meta_issue": "14", "meta_pages": "e0068822", "score": 50244.383, "text_hl": "It showed that two drugs, @CHEMICAL_Deoxyglucose @CHEMICAL_MESH:D003847 @@@2-deoxy-d-glucose@@@ (@CHEMICAL_Deoxyglucose @CHEMICAL_MESH:D003847 @@@2DG@@@) and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, effectively diminished @<m>DISEASE_Eye_Infections_Fungal</m> @DISEASE_MESH:D015821 @@@ocular lesion@@@ expression, but only @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ avoided the complication of HSV spreading to the central nervous system (CNS) and causing @DISEASE_Encephalitis_Herpes_Simplex @DISEASE_MESH:D020803 @@@herpetic encephalitis@@@. ", "citations": {"NLM": "Berber E, Rouse BT. Controlling Herpes Simplex Virus-Induced Immunoinflammatory Lesions Using Metabolic Therapy: a Comparison of 2-Deoxy-d-Glucose with Metformin. J Virol. 2022 Jul 27;96(14):e0068822. PMID: 35862706", "BibTeX": "@article{35862706, title={Controlling Herpes Simplex Virus-Induced Immunoinflammatory Lesions Using Metabolic Therapy: a Comparison of 2-Deoxy-d-Glucose with Metformin.}, author={Berber E and Rouse BT}, journal={J Virol}, volume={96}, number={14}, pages={e0068822}}"}}, {"_id": "26150733", "pmid": 26150733, "pmcid": "PMC4485795", "title": "Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination", "journal": "Diabetes Metab Syndr Obes", "authors": ["Fleming JW", "Fleming LW", "Davis CS"], "date": "2015-06-25T00:00:00Z", "doi": "10.2147/DMSO.S69282", "meta_date_publication": "2015", "meta_volume": "8", "meta_issue": "", "meta_pages": "287-94", "score": 50051.43, "text_hl": "The primary disadvantages are potential @<m>DISEASE_Eye_Infections_Fungal</m> @DISEASE_MESH:D015821 @@@genital mycotic infections@@@, @DISEASE_Hypotension @DISEASE_MESH:D007022 @@@hypotension@@@, and @DISEASE_Drug_Related_Side_Effects_and_Adverse_Reactions @DISEASE_MESH:D064420 @@@gastrointestinal side effects@@@ from @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Fleming JW, Fleming LW, Davis CS. Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination Diabetes Metab Syndr Obes. 2015;8():287-94. PMID: 26150733", "BibTeX": "@article{26150733, title={Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination}, author={Fleming JW and Fleming LW and Davis CS}, journal={Diabetes Metab Syndr Obes}, volume={8}, pages={287-94}}"}}, {"_id": "26786577", "pmid": 26786577, "title": "Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naive Type 2 Diabetes.", "journal": "Diabetes Care", "authors": ["Rosenstock J", "Chuck L", "González-Ortiz M", "Merton K", "Craig J", "Capuano G", "Qiu R"], "date": "2016-03-01T00:00:00Z", "doi": "10.2337/dc15-1736", "meta_date_publication": "2016 Mar", "meta_volume": "39", "meta_issue": "3", "meta_pages": "353-62", "score": 50044.105, "text_hl": "Initial Combination Therapy With @CHEMICAL_Canagliflozin @CHEMICAL_MESH:D000068896 @@@Canagliflozin@@@ Plus @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Versus Each Component as Monotherapy for Drug-Naive @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@Type 2 Diabetes@@@.", "citations": {"NLM": "Rosenstock J, Chuck L, González-Ortiz M, Merton K, Craig J, Capuano G, Qiu R. Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naive Type 2 Diabetes. Diabetes Care. 2016 Mar;39(3):353-62. PMID: 26786577", "BibTeX": "@article{26786577, title={Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naive Type 2 Diabetes.}, author={Rosenstock J and Chuck L and González-Ortiz M and Merton K and Craig J and Capuano G and Qiu R}, journal={Diabetes Care}, volume={39}, number={3}, pages={353-62}}"}}, {"_id": "27227214", "pmid": 27227214, "title": "Diabetes Medications for Adults With Type 2 Diabetes: An Update", "journal": "", "authors": ["Bolen S", "Tseng E", "Hutfless S", "Segal JB", "Suarez-Cuervo C", "Berger Z", "Wilson LM", "Chu Y", "Iyoha E", "Maruthur NM"], "date": "2016-04-01T00:00:00Z", "meta_date_publication": "2016 Apr", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50042.465, "text_hl": "SGLT-2 inhibitors and @GENE_GLP1R @GENE_2740 @@@GLP-1@@@ agonists plus @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ reduced systolic blood pressure by 3 to 5 mmHg compared with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Bolen S, Tseng E, Hutfless S, Segal JB, Suarez-Cuervo C, Berger Z, Wilson LM, Chu Y, Iyoha E, Maruthur NM. Diabetes Medications for Adults With Type 2 Diabetes: An Update . 2016 Apr;():. PMID: 27227214", "BibTeX": "@article{27227214, title={Diabetes Medications for Adults With Type 2 Diabetes: An Update}, author={Bolen S and Tseng E and Hutfless S and Segal JB and Suarez-Cuervo C and Berger Z and Wilson LM and Chu Y and Iyoha E and Maruthur NM}}"}}, {"_id": "24026211", "pmid": 24026211, "pmcid": "PMC3825495", "title": "Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial", "journal": "Diabetologia", "authors": ["Lavalle-González FJ", "Januszewicz A", "Davidson J", "Tong C", "Qiu R", "Canovatchel W", "Meininger G"], "date": "2013-12-01T00:00:00Z", "doi": "10.1007/s00125-013-3039-1", "meta_date_publication": "2013 Dec", "meta_volume": "56", "meta_issue": "12", "meta_pages": "2582-92", "score": 50039.086, "text_hl": "Those on @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ extended release (XR), @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ IR or XR at below protocol-specified doses or @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ plus @CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@sulfonylurea@@@ underwent a @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ IR dose titration/dose stable and, if applicable, a @CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@sulfonylurea@@@ washout period of up to 10 weeks, followed by the placebo run-in period.", "citations": {"NLM": "Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Diabetologia. 2013 Dec;56(12):2582-92. PMID: 24026211", "BibTeX": "@article{24026211, title={Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial}, author={Lavalle-González FJ and Januszewicz A and Davidson J and Tong C and Qiu R and Canovatchel W and Meininger G}, journal={Diabetologia}, volume={56}, number={12}, pages={2582-92}}"}}]}